Overview
On 20 December 2007, orphan designation (EU/3/07/516) was granted by the European Commission to SymbioTec GmbH, Germany, for recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3 for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to Xenetic Biosciences Plc, United Kingdom, in October 2012.
Key facts
Active substance |
Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3
|
Intended use |
Treatment of acute myeloid leukaemia
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/07/516
|
Date of designation |
20/12/2007
|
Sponsor |
Xenetic Biosciences Plc
London Bioscience Innovation Centre 2 Royal College Street London NW1 0NH United Kingdom Tel. +44 (0)20 7691 4906 Fax +44 (0)20 7916 9771 E-mail: bd@xeneticbio.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: